Glioblastoma Cancer Clinical Trial
Glioblastoma (GBM) is an aggressive and frequently lethal brain malignancy, which is usually resistant to conventional therapies and immunotherapies. GBM has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors.
We are currently developing a protocol to treat recurrent glioblastoma using Aldoxorubicin and our Anktiva.
This unique approach to orchestrating the innate and adaptive immune systems to induce immunogenic cell death may be an important new approach for pancreatic cancer patients—these being among the most challenging to treat with poor prognosis.